Entacom Plus 150 Tablet is a combination pharmaceutical formulation containing Levodopa (150 mg), Carbidopa (37.5 mg), and Entacapone (200 mg), primarily indicated for the management of Parkinson’s disease. Levodopa serves as a precursor to dopamine, replenishing depleted dopamine levels in the brain, thereby alleviating motor symptoms such as bradykinesia, rigidity, and tremors. Carbidopa, a peripheral dopa-decarboxylase inhibitor, enhances the bioavailability of Levodopa by preventing its premature conversion to dopamine outside the central nervous system, reducing peripheral side effects like nausea and cardiovascular disturbances. Entacapone, a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, prolongs the half-life of Levodopa by inhibiting its metabolism, thereby improving and extending symptomatic control. The combined action of these agents optimizes dopaminergic stimulation in the striatum, providing improved motor function and reducing “wearing-off” phenomena commonly observed in long-term Levodopa therapy. Entacom Plus 150 is administered orally, with dosage individualized based on clinical response and tolerability. Caution is advised in patients with cardiovascular disorders, hepatic impairment, or history of neuroleptic malignant syndrome. Regular monitoring is recommended to assess therapeutic efficacy and adverse effects. This combination offers a comprehensive approach to Parkinson’s disease management, enhancing patient quality of life through improved symptom control.